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Abstract
Chemokine CXCL12 is proposed to promotemultiple steps in growth of primary tumors and progression tometastatic
disease in more than 20 different cancers. Functions of CXCL12 previously were believed to be controlled only by
receptor CXCR4, but CXCR7 was recently identified as a second receptor for this chemokine. CXCR7 increases tumor
formation andmetastasis in mousemodels, suggesting that this receptor may also be a key target for blocking effects
of CXCL12 in cancer. To image activation of CXCR7 in intact cells and living mice, we tested the hypothesis that
binding of chemokine ligands to CXCR7 recruits β-arrestins, a family of cytosolic adapter proteins that interact with
many activated chemokine and related seven-transmembrane receptors. Using firefly luciferase protein fragment
complementation, we established that chemokine ligands CXCL12 and CXCL11 significantly increase association
of CXCR7 and β-arrestins with preferential interaction of the receptor with β-arrestin 2. The magnitude of interactions
between CXCR7 and β-arrestin 2 increased over time after treatment with ligands, contrasting with transient as-
sociation of β-arrestin 2 and CXCR4. β-Arrestin 2 increased uptake of CXCL12 in cells expressing CXCR7, emphasiz-
ing the functional relevance of the interaction between CXCR7 and β-arrestin 2. In an orthotopic xenograft model
of human breast cancer, we used bioluminescence imaging to quantify changes in the association of CXCR7 and
β-arrestin 2. These studies demonstrate ligand-dependent interactions of CXCR7 with β-arrestin 2 that promote ac-
cumulation of chemokines and establish an imaging assay for the dynamic regulation of CXCR7 by chemokines and
candidate therapeutic agents in cell-based assays and living mice.
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Introduction
Chemokine receptors are members of the large family of seven-
transmembrane (7-TM) receptors, also referred to as G-protein–
coupled receptors. Chemokine receptors were initially identified because
of functions in trafficking of hematopoietic cells under physiologic
conditions and in response to inflammatory stimuli. More recently, it
has become evident that many different types of cancer cells co-opt
chemokine receptors to promote growth of primary tumors, metastasis,
and resistance to chemotherapy. The emerging roles of chemokines and
their receptors in cancer are motivating ongoing efforts to target these
pathways therapeutically [1].
In particular, chemokine CXCL12 has been linked to multiple
key processes in cancer, including cell proliferation, survival, migra-
tion, invasion, and chemotaxis of cancer cells to characteristic sites of
metastasis [2–7]. Effects of CXCL12 in normal physiology and cancer
have been ascribed to signaling through receptor CXCR4 [8,9] based
in large part on the comparable phenotypes of mice lacking either
CXCL12 or CXCR4 [10–12]. Work by our laboratory and others
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has shown that CXCL12-CXCR4 signaling increases growth of ortho-
topic breast cancer xenografts and both spontaneous and experimentally
induced metastases [13–15]. Indeed, studies have shown similar effects
of CXCL12-CXCR4 in more than 20 types of cancer, providing com-
pelling evidence for the importance of this chemokine signaling path-
way in cancer.
Recently, CXCR7 was identified as a second chemokine receptor for
CXCL12, suggesting that functions of CXCL12 in cancer may be
regulated at least in part through this receptor. CXCR7 also binds to
chemokine CXCL11, a molecule that has been implicated in cancer
progression through binding to receptor CXCR3 [16]. We have shown
that expression of CXCR7 promotes growth and metastasis of breast
and lung cancer cells in animal models, and similar results have been
obtained in a mouse model of prostate cancer [17,18]. Whereas these
studies strongly link CXCR7 to cancer biology, functions of CXCR7
and its molecular interactions in cells after ligand binding remain poorly
defined and controversial. Some studies suggest that CXCR7 functions
as a signaling receptor, promoting cell adhesion, chemotaxis, and ac-
tivation of downstream signaling molecules such as AKT [18–22].
However, these effects of CXCR7 have not been identified consistently
in different model systems [23,24]. CXCR7 may heterodimerize with
CXCR4 and modulate signaling pathways initiated through CXCL12-
CXCR4 [25,26], but some effects of CXCR7 in growth and metastasis
of cancer cells and cell migration seem to be independent of CXCR4
[17,27]. Recent data also suggest that CXCR7may act as a decoy recep-
tor to scavenge CXCL12 and establish appropriate gradients of this
chemokine for germ cell migration in zebrafish [24]. Collectively, these
data highlight complex functions of CXCR7 in both normal develop-
ment and cancer, emphasizing the need to define fundamental mecha-
nisms of receptor activation.
Ligand binding to most chemokine receptors, like other 7-TM re-
ceptors, activates the receptor and leads to phosphorylation of the re-
ceptor by a G protein receptor kinase (GRK; reviewed in Moore et al.
[28]). Phosphorylation of the receptor causes recruitment of a cyto-
solic adapter protein, β-arrestin. The complex of ligand, receptor, and
β-arrestin is then internalized, removing the receptor from the cell
membrane. However, internalization of 7-TM receptors may be in-
dependent of β-arrestin [29], including some members of the class
of decoy chemokine receptors [30,31]. Decoy chemokine receptors
bind chemokine ligands and internalize without initiating signaling
pathways characteristically associated with activated chemokine recep-
tors. Such decoy receptors, including CCX-CKR and Darc, apparently
function to sequester chemokines, limiting inflammation and/or main-
taining well-defined gradients of chemokines for signaling through
other receptors.
Because CXCR7 may have functions of both signaling and decoy
chemokine receptors, we investigated the effects of chemokine ligands
on binding of the receptor to β-arrestin molecules. To accomplish this
goal, we used a protein fragment complementation assay (PCA) based
on firefly luciferase [32]. The luciferase enzyme fragments have mini-
mal background association when coexpressed as individual proteins
in the same cell. When these enzyme fragments are fused to interact-
ing proteins, association of the target proteins reconstitutes active fire-
fly luciferase enzyme. Therefore, changes in luciferase activity can be
used to quantify the magnitude and kinetics of protein interactions
in intact cells and living animals. We recently used this PCA strategy
to analyze chemokine-dependent interactions ofCXCR4with β-arrestin
molecules, validating the system for our current investigation of CXCR7
and β-arrestin [33]. Using this PCA, we established that chemokines
drive recruitment of β-arrestin molecules to CXCR7 and show that the
receptor preferentially interacts with β-arrestin 2 relative to β-arrestin 1.
Unlike the brief interaction between CXCR4 and β-arrestin 2, associa-
tion of CXCR7 with β-arrestin 2 increased over time. Loss of functional
β-arrestin 2 reduced CXCR7-dependent uptake of CXCL12 from the
extracellular space, establishing that β-arrestin 2 is necessary for this func-
tion of the receptor. Using association of β-arrestin 2 and CXCR7 as a
marker of receptor activation, we were able to image in vivo regulation
of this receptor in human breast tumor xenografts after treatment with
a CXCR7-targeted small molecule. By enabling CXCR7 activation to
be quantified in intact cells and the in vivo tumor microenvironment, this
imaging strategy will advance functional studies of CXCR7 and acceler-
ate identification and validation of CXCR7-targeted therapeutic agents.
Experimental Procedures
DNA Constructs
Luciferase complementation plasmids in vector pEF for N- and
C-terminal fragments of firefly luciferase (NLuc and CLuc) and c-fos
fused to CLuc (fos-CLuc) were provided by Alnawaz Rehemtulla
(University of Michigan). CLuc-FKBP12 was provided by David
Piwnica-Worms (Washington University) [32]. A plasmid expressing
constitutively active GRK2 (GRK2-C20) was provided by John Tesmer
(University of Michigan). Plasmids for human CXCR4 or CXCR7
fused to NLuc or CLuc, β-arrestin 1 and β-arrestin 2 fused to CLuc,
and CXCL12 fused to Gaussia luciferase (CXCL12-GL) have been
described previously [33–35]. Plasmids for firefly and Gaussia lucif-
erases (pGL3-control and pCMV-GL, respectively) were from Promega
(Madison, WI).
CXCR7–green fluorescent protein (GFP) and CXCR7-mPlum were
generated by amplifying CXCR7 with polymerase chain reaction
(PCR) primers 5′-ATTACTCGAGACCGCCATGGATCTGCATC-
TCTTCGACTA-3′ and 5′-TAATGACCGGTCCACCGCCTGA-
AGAACCGCCTCCTTTGGTGCTCTGCTCCAAGGCAG-3′ and
ligating the product into corresponding XhoI and AgeI sites of vector
EGFP-N1 (BD Biosciences, San Jose, CA) or mPlum in the same
N1 vector (a gift from Roger Tsien, University of California, San Diego,
CA; restriction sites added for cloning are underlined) [36]. The
C-terminus of β-arrestin 2 was fused to fluorescent protein mCherry
(a gift from Roger Tsien) by amplifying mCherry with PCR primers
5′-ATCCACCGGTCGGCGGTGGCTCATCTGGCGGAGGTGT-
GAGCAAGGGCGAGGAGGATAAC-3′ and 5′-GCATGCGG-
CCGCCTACTTGTACAGCTCGTCCATG-3′. Restriction sites for
AgeI andNotI, respectively, are underlined. The PCR product was ligated
to the corresponding sites in plasmid β-arrestin 2–CLuc [33], removing
the C-terminal fragment of firefly luciferase. All PCR products were
verified by DNA sequencing.
Cells
Human embryonic kidney 293 cells stably expressing large Tantigen
from SV40 virus (293T; Open Biosystems, Huntsville, AL), human
MDA-MB-231 and MCF-7 breast cancer cells (ATCC, Manassas,
VA), and wild-type and β-arrestin 2−/− mouse embryonic fibroblasts
(MEFs; gift from Robert Lefkowitz, Duke University) were cultured in
Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA), 10%
fetal bovine serum, 1% glutamine, and 0.1% penicillin/streptomycin/
gentamicin. Cells were maintained in a 37°C incubator with 5% CO2.
293T cells stably expressing CXCL12-GL and unfused GL have been
described previously [35].
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To generate stable cell lines coexpressing CXCR7-NLuc and β-arrestin
2–CLuc or fos-CLuc, we prepared recombinant lentiviruses express-
ing each of these proteins as described previously [14,37]. 293T or
231 cells were first transduced with supernatants containing CXCR7-
NLuc in FUGW. Transduction efficiency was 100% as determined by
fluorescence microscopy. These cells were then transduced with super-
natants for β-arrestin 2–CLuc or fos-CLuc in FUPW. Again, all cells were
transduced with CLuc constructs as determined by fluorescence micros-
copy for mPlum. Batch populations of 293T reporter cells were used
for all experiments, whereas clonal cell lines of 231 cells transduced with
CXCR7-NLuc and β-arrestin–2-CLuc were isolated for cell culture and
animal studies. Wild-type or β-arrestin 2−/− MEFs were transduced with
lentiviruses expressing CXCR7-GFP, and batch populations of trans-
duced MEF lines were used for all experiments.
CXCL12-GL and Unfused GL Supernatants
Supernatants with CXCL12-GL or unfused GL were prepared from
stably transduced 293T cells as described previously [35].
Live Cell Bioluminescence Imaging
293T cells were transfected with firefly luciferase complementation
plasmids by calcium phosphate precipitation as described previously
[37]. Cells were also cotransfected with constitutively expressed GL as
a transfection control. One day after transfection, cells were split
into black-walled 96-well plates (Corning, Lowell, MA) at 1 × 104 cells
per well using aMultidrop 384 dispensing system (Labsystems,Waltham,
MA), and experiments were performed 2 days after transfection. For
competition experiments with CXCR4 or CXCR7, 293T cells stably ex-
pressing the CXCR7/β-arrestin 2 luciferase complementation pair were
transiently transfected with 3.5 μg per 6-cm dish of CXCR4-mPlum
or CXCR7-mPlum. These cells were split into 96-well plates the fol-
lowing day and used for assays 2 days after transfection. For other ex-
periments with stable cell lines, cells were plated into 96-well plates as
described previously 1 day before each assay. Quadruplicate samples were
used for all experimental conditions. Cells were treated with various con-
centrations of CXCL11, CXCL12 (R&D Systems, Minneapolis, MN),
AMD3100 (Sigma, St. Louis, MO), TF14013 (a gift from N. Fujii), or
CCX733 or CCX754 (a gift from Chemocentryx, Mountain View, CA)
as described in figure legends. Incubation times for each agent are also
listed in figure legends.
To quantify uptake of CXCL12-GL or unfused GL, stably transduced
MEFs were plated at 1.2 × 104 cells per well in black-walled 96-well
plates 1 day before experiments. MEFs were wild-type or β-arrestin
2−/− cell lines stably expressing CXCR7-GFP. Cells were incubated with
≈10 ng/ml CXCL12-GL or a comparable amount of unfused GL based
on bioluminescence for 1 hour. At the end of the incubation period,
cells were washed twice with either phosphate-buffered saline (PBS) at
room temperature or an acidic solution (0.2 M acetic acid, 0.5 MNaCl)
at 4°C. Washing with acidic solution removes chemokine bound to the
cell surface [38]. Cells were then washed once with PBS to restore neutral
pH. Bioluminescence was quantified immediately after adding 1 μg/ml
coelenterazine diluted in PBS (Fluka, St. Louis, MO).
Bioluminescence imaging of firefly luciferase activity in live cells was
performed on a cryogenically cooled camera system (IVIS 100; Caliper,
Hopkinton, MA) as described previously [32], using 1- to 5-minute ac-
quisition times, high sensitivity, and field of view B. Imaging parameters
for accumulation of CXCL12-GL were 2-minute acquisition, medium
sensitivity, and field of view B. For firefly luciferase complementation
experiments with transiently transfected cells, GL activity was measured
in parallel wells of transfected cells incubatedwith 1μg/ml coelenterazine.
Bioluminescence was assayed on the IVIS using 1- to 2-minute acquisi-
tion, medium sensitivity, and field of view B immediately after adding
coelenterazine. Previous research has shown that amounts of GL are
directly related to the numbers of cells expressing this enzyme [39].
The same protocol was used to quantify amounts of CXCL12-GL or un-
fused GL in experiments with MEFs. For transient transfections with
luciferase complementation, data for firefly luciferase activity were nor-
malized to GL activity to account for differences in transfection efficiency
and numbers of cells. Data for stable cell lines and cellular accumulation
of CXCL12-GL were normalized to total protein per well measured by
sulforhodamine B staining [40].
Fluorescence Microscopy
293T cells were transiently transfected withCXCR7-GFPand a wild-
type or mutant β-arrestin 2–mCherry plasmid as described previously,
split into 35-mmdishes with glass bottoms (MatTek, Ashland,MA) and
then used for experiments 2 days after transfection. Cells were treated
with 300 ng/ml CXCL12 for 2 hours and then imaged by epifluorescence
microscopy using a 40× objective (Olympus, Center Valley, PA). Fluo-
rescence images were obtained with Spot Advanced software (Sterling
Heights, MI), and merged images were created with Adobe Photoshop
(San Jose, CA).
Flow Cytometry
Cell surface expression of CXCR7 was quantified with monoclonal
antibody 11G8 as we have described previously [17].
In Vivo Bioluminescence Imaging
All animal procedures were approved by the University of Michigan
Committee for Use and Care of Animals. A total of 1 × 106 MDA-
MB-231 human breast cancer cells stably coexpressing CXCR7-NLuc
and β-arrestin–2-CLuc were orthotopically implanted into bilateral
inguinal mammary fat pads of 6-week-old female severe combined
immunodeficient (SCID) mice (Taconic, Hudson, NY) [14]. After tu-
mors reached approximately 8 to 10 mm in diameter, animals were
injected subcutaneously with CCX754 or vehicle control (a gift from
Chemocentryx) [20] at times and amounts listed in the figure legend.
Bioluminescence imaging was performed on an IVIS spectrum system
(Caliper) as we have described previously [41]. Data for bioluminescence
were quantified as photons using Living Image software (Caliper). Photon
data for bioluminescence after injection with CCX754 or vehicle were
normalized to pretreatment images to account for differences in volumes
of various tumors.
Statistics
Data are plotted as mean values with SEM. Pairs of data were
analyzed by t test to determine statistically significant differences
(GraphPad Prism, La Jolla, CA).
Results
Recruitment of β-Arrestin to CXCR7
In response to ligand binding, chemokine receptors and other 7-TM
receptors typically are phosphorylated by a GRK, resulting in the inter-
action of the phosphorylated receptor with a cytoplasmic adapter pro-
tein, β-arrestin. β-Arrestin then recruits the 7-TM receptor to clathrin
and clathrin-coated pits, resulting in the internalization of the complex
of β-arrestin and 7-TM receptor. However, some chemokine decoy
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receptors, such as D6, may cycle constitutively without ligand-induced
binding to β-arrestin [42], and other chemokine decoy receptors, in-
cluding Darc and CCX-CKR, do not interact with β-arrestin [30,31].
Because recent studies suggest that CXCR7 may function at least in
part as a decoy chemokine receptor for CXCL12, we investigated the
interactions of CXCR7 with β-arrestin and the effects of ligands on
this process.
To analyze association of CXCR7 and β-arrestin molecules, we used
a firefly luciferase PCA that we recently validated for analyzing inter-
actions between CXCR4 and β-arrestin in intact cells and living mice
[33]. The PCA uses N- and C-terminal fragments of firefly luciferase
(NLuc and CLuc, respectively) that have essentially undetectable bio-
luminescence when expressed singly or together in living cells [32].
When NLuc and CLuc are fused to proteins of interest, association
of the target proteins also reconstitutes luciferase activity, providing a
quantitative measure of the magnitude and kinetics of protein inter-
actions. We fused the intracellular C-terminus of CXCR7 to NLuc
(CXCR7-NLuc) and β-arrestin 2 to CLuc (β-arrestin 2–CLuc), analo-
gous to our PCA for CXCR4 and β-arrestin 2 (Figure 1A). As nega-
tive controls, we used either c-fos, a cytoplasmic protein not known
Figure 1. Firefly luciferase PCA for recruitment of β-arrestin to CXCR7. (A) Diagram of PCA showing fusion of the NLuc and CLuc frag-
ments of firefly luciferase to the 7-TM receptor CXCR7 and the cytoplasmic adapter molecule β-arrestin 2, respectively. Binding of
CXCL11 or CXCL12 to CXCR7 recruits β-arrestin 2 to the receptor, bringing NLuc and CLuc enzyme fragments into proximity and re-
constituting firefly luciferase activity. Bioluminescence provides a quantitative measure of the magnitude and kinetics of protein inter-
actions between CXCR7 and β-arrestin. (B) 293T cells were transfected transiently with CXCR7-NLuc, and cell surface expression of the
receptor was determined by flow cytometry 48 hours later. Endogenous expression of CXCR7 in MCF-7 human breast cancer cells is
shown for comparison. Open symbol indicates isotype control; solid symbol, antibody to CXCR7. (C) 293T cells were transfected tran-
siently with PCA reporters CXCR7-NLuc and β-arrestin 2–CLuc and a plasmid for constitutively active GRK2 (GRK2-C20) or empty vector
control (n= 4 per condition). Cells were also cotransfected with an expression plasmid for GL as a control for transfection efficiency. Firefly
luciferase bioluminescence in intact cells was quantified 48 hours after transfection and normalized to GL activity. Data are mean values ±
SEM representative of three independent experiments. ***P < .005.
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to associate with 7-TM receptors, fused to CLuc (fos-CLuc) or CLuc-
FKBP12, a fusion protein that we previously have shown to interact
with FRB-NLuc in a rapamycin-dependent manner [32]. Expression
of CXCR7-NLuc was verified by flow cytometry (Figure 1B), whereas
cell membrane expression of the receptor was undetectable in con-
trol 293T cells (data not shown). Levels of CXCR7 on the surface of
transiently transfected 293T cells were only slightly greater than the
amounts expressed endogenously by MCF-7 human breast cancer
cells. We previously have established that our constructs for β-arrestin
2–CLuc, fos-CLuc, and CLuc-FKBP12 fusion proteins express in
293T cells and note that these cells express higher levels of endogenous
β-arrestin 2 than many other commonly used cell lines [32,33,43].
As an initial test of phosphorylation-dependent recruitment of
β-arrestin 2 to CXCR7, we transiently transfected cells with CXCR7-
NLuc and a plasmid for β-arrestin 2–CLuc, fos-CLuc, or CLuc-
FKBP12, respectively. Separate cells were also transfected with only
one of the four complementation vectors alone. To drive phosphoryla-
tion of CXCR7, we cotransfected cells with isoprenylated, constitutively
active GRK2 or empty vector [44]. Forty-eight hours after transfection,
bioluminescence from the interaction of CXCR7-NLuc and β-arrestin
2–CLuc was increased by ≈10-fold in cells expressing constitutively
active GRK2 relative to vector control (Figure 1C ; P < .005). By com-
parison, bioluminescence produced by the combination of CXCR7-
NLuc and fos-CLuc or CXCR7-NLuc and CLuc-FKBP12 was not
detectable above background, showing specificity of the interaction
between CXCR7 and β-arrestin 2 (data not shown). Cells transfected
with CXCR7-NLuc, β-arrestin 2–CLuc, fos-CLuc, and CLuc-FKBP12
alone also did not produce bioluminescence above background lev-
els (data not shown). These data demonstrate that the association
of CXCR7 and β-arrestin 2 is increased substantially in response to
GRK activity.
Having established that CXCR7 interacts with β-arrestin 2, we com-
pared the magnitude of basal and ligand-dependent recruitment of
β-arrestin 2 to CXCR7 relative to CXCR4. CXCR4 is the only other
chemokine receptor known to bind chemokine CXCL12. We used
batch populations of 293T cells stably transduced with PCA reporters
for CXCR7-NLuc/β-arrestin 2–CLuc or CXCR7-NLuc/fos-CLuc,
in addition to our previously described stable cell lines for CXCR4-
NLuc/β-arrestin 2–CLuc or CXCR4-NLuc/fos-CLuc [33]. We treated
cells with either CXCL12, which binds to both CXCR4 and CXCR7,
or CXCL11, a chemokine that is recognized by CXCR7 but not
CXCR4 [19,20]. We measured bioluminescence in intact cells under
basal conditions and ≈10 minutes after adding chemokines.
In the absence of chemokines, there was more luciferase activity
in CXCR7-NLuc/β-arrestin 2–CLuc cells compared with cells ex-
pressing the CXCR4 reporter, suggesting a higher basal association
of β-arrestin 2 with CXCR7 (Figure 2). Approximately 10minutes after
adding CXCL11 or CXCL12, bioluminescence increased by ≈1.5-fold
above baseline for cells expressing CXCR7-NLuc/β-arrestin 2–CLuc
(P < .05). By comparison, incubation with CXCL12 increased bio-
luminescence by approximately six-fold for recruitment of β-arrestin
2–CLuc to CXCR4-NLuc (P < .005). Treatment of CXCR4-NLuc/
β-arrestin 2–CLuc cells with CXCL11 did not alter baseline association
of these proteins, showing specificity of the assay for ligand-receptor
binding. Bioluminescence from cells coexpressing fos-CLuc with either
CXCR4- or CXCR7-NLuc did not differ from 293T cells without any
firefly luciferase fragments. Overall, these data demonstrate that im-
mediate recruitment of β-arrestin 2 to CXCR7 is substantially less than
CXCR4 in response to chemokine ligands.
Kinetics of Ligand-Dependent Recruitment of β-Arrestin 2
to CXCR7
In the initial experiments described in the previous paragraphs, we
measured luciferase activity shortly after treating cells with a chemokine.
This experimental protocol was based on our previous research with
CXCR4 in which bioluminescence from recruitment of β-arrestin 2 to
this receptor peaked ≈5 to 10 minutes after adding CXCL12 and then
returned to basal levels within 40 minutes [33]. A relatively brief associa-
tion of CXCR4with β-arrestin 2 characterizes a subset of 7-TM receptors
defined as class A [28,45]. However, other 7-TM receptors form more
prolonged interactions with β-arrestin 2 in intracellular compartments,
defining class B receptors. The existence of these two different classes sug-
gested that kinetics of interaction between CXCR7 and β-arrestin 2 may
be substantially longer for this receptor relative to CXCR4.
To analyze the time course of β-arrestin 2 recruitment to CXCR7, we
treated stable 293T CXCR7-NLuc/β-arrestin 2–CLuc PCA cells with
Figure 2. Chemokine-dependent recruitment of β-arrestin 2 to CXCR7. 293T cells stably expressing firefly luciferase PCA reporters for
CXCR7-NLuc/β-arrestin 2–CLuc, CXCR7-NLuc/fos-CLuc, CXCR4-NLuc/β-arrestin 2–CLuc, or CXCR4-NLuc/fos-CLuc were treated with
1 μg/ml CXCL11 or CXCL12. Bioluminescence produced by intact cells was quantified ≈10 minutes after adding chemokine or medium
alone (n = 4 per condition). Parental 293T cells not expressing any firefly luciferase PCA reporters are shown for comparison. Data are
mean values for firefly luciferase activity ± SEM and are representative of four independent experiments. *P < .05; ***P < .005.
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increasing concentrations of CXCL11 or CXCL12 for periods extending
up to 4 hours beforemeasuring luciferase activity in living cells. Incubation
with CXCL11 or CXCL12 produced both time- and dose-dependent
increases in bioluminescence from recruitment of β-arrestin 2 to CXCR7
(Figure 3, A and B). For example, treatment with 1 μg/ml CXCL12
increased bioluminescence by 1.3-fold above baseline levels 5 minutes
after adding chemokine to cells, whereas the reporter signal fromCXCR7
and β-arrestin 2 increased by four-fold after 4 hours of continuous in-
cubation (P < .01). We observed similar kinetics and changes in the
magnitude of bioluminescence after treatment with CXCL11.
We also investigated a reversal of association between CXCR7
and β-arrestin 2 after extended treatment with the chemokine ligand.
We incubated stable reporter cells with 10 ng/ml CXCL12 or vehicle
control for 2 hours to stimulate an interaction between CXCR4 and
β-arrestin 2. Cells were washed with PBS and then incubated in a
medium without chemokine for an additional 0.5 or 4 hours before
quantifying luciferase activity in intact cells. Incubation with CXCL12
increased bioluminescence from the interaction of CXCR7 and β-
arrestin 2 by more than 2.5-fold above control cells (Figure 3C ).
PCA signal decreased by ≈50% in the first 30 minutes after removing
CXCL12 and decreased to ≈35% above control levels by 4 hours. These
data demonstrate that most CXCR7–β-arrestin 2 complexes dissociate
after removing the chemokine ligand, approaching the basal level of
interaction between these two proteins in unstimulated cells.
To directly compare responses of β-arrestin 2 recruitment to CXCR4
versus CXCR7, we incubated stable reporter cell lines with 100 ng/ml
CXCL12 and quantified luciferase activity within the first 10 minutes
after adding chemokine or after 2 hours of continuous incubation (Fig-
ure 3D). Recruitment of β-arrestin 2 to CXCR4 occurred rapidly in
response to CXCL12 and returned to baseline values by 2 hours. By
comparison, the interaction of CXCR7 with β-arrestin 2 showed the
opposite pattern with very low levels of bioluminescence produced
within the first 10 minutes and more than a three-fold induction of
luciferase activity above baseline after 2 hours. These experiments show
that continuous exposure to chemokine ligands drives progressive in-
creases in association of β-arrestin 2 with CXCR7, contrasting with
the rapid onset and short duration of this process for CXCR4 and most
other chemokine receptors.
We also used fluorescence microscopy to verify recruitment of
β-arrestin 2 to CXCR7. 293T cells were transfected with CXCR7
Figure 3. Time- and dose-dependent recruitment of β-arrestin 2 to CXCR7 in response to chemokine ligands. (A and B) Stably transduced
CXCR7/β-arrestin 2 PCA reporter cells were incubated with increasing concentrations of CXCL11 (A) or CXCL12 (B) for various periods before
quantifying bioluminescence in intact cells (n = 4, representative of three independent experiments). Data are reported as the fold increase
in photons relative to control values in unstimulated cells. Error bars, SEM. (C) Reporter cells were incubated with 10 ng/ml CXCL12 for
2 hours, washed with PBS, and then incubated without chemokine for 0.5 or 4 hours of washout. Control cells were maintained in normal
medium with no added chemokine. Data are expressed as mean values ± SEM relative to a value of 1 for control cells (n = 4 per condition,
representative of two independent experiments). (D) 293T cells stably transduced with the CXCR7/β-arrestin 2 PCA or CXCR4/β-arrestin 2
PCA reporter were incubated with 100 ng/ml CXCL12 for either 10 minutes or 2 hours before quantifying firefly luciferase activity in living
cells (n = 4 per condition). Data are presented as the increase in luminescence relative to baseline values in untreated cells with error bars
denoting SEM. Results are representative of three independent experiments. *P < .05; **P < .01; ***P < .005.
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and β-arrestin 2 fused to GFP and mCherry, respectively, and then
imaged before and after treatment with 300 ng/ml CXCL12 or BSA
control for 2 hours. Under basal conditions, CXCR7-GFP predomi-
nantly localized intracellularly as has been described previously [24],
whereas β-arrestin 2–mCherry distributed diffusely throughout the
cytoplasm with a limited number of more discrete intracellular foci
(Figure 4). After treatment with CXCL12, β-arrestin 2 was present in
more numerous intracellular structures that frequently had a ringlike
appearance suggestive of vesicles. Many of these foci of β-arrestin 2
colocalized with CXCR7. By comparison, treatment with BSA did not
alter distribution of β-arrestin 2 from the basal state (data not shown)
and/or affect colocalization with CXCR7. In combination with data
from luciferase complementation assays, results from fluorescence
microscopy show that CXCL12 promotes association of CXCR7 with
β-arrestin 2, predominantly on intracellular structures.
Effects of Nonbioluminescent CXCR4 or CXCR7 on
Complementation Signal
To investigate luciferase complementation in the presence of CXCR4
or CXCR7 receptors without an enzyme fragment, we transiently ex-
pressed CXCR4-mPlum or CXCR7-mPlum in 293T cells stably express-
ing the CXCR7/β-arrestin 2 complementation pair. Cells transfected
with unfusedmPlumwere used as a control. All fluorescent proteins were
expressed in comparable numbers of cells based on fluorescence micros-
copy (data not shown). After treatment for 2 hours with 300 ng/ml
CXCL12, luciferase activity was approximately 35% (P < .05) and
50% (P < .01) lower in cells coexpressing nonbioluminescent CXCR4
or CXCR7, respectively, relative to control cells (Figure 5). Differ-
ences between nonbioluminescent CXCR4 and CXCR7 to reduce lu-
ciferase activity were also significant (P < .05). Luciferase activity from
the CXCR7-NLuc/β-arrestin 2–CLuc PCA also increased in response
to CXCL12 when constructs were expressed stably in human MCF-7
breast cancer cells, a cell line that endogenously expresses CXCR4 and
CXCR7 (data not shown) [20,46]. Collectively, these data show that
the CXCR7/β-arrestin 2 complementation pair functions in the context
of nonbioluminescent chemokine receptors, although the magnitude
of induction is less than in cells lacking CXCR4 and CXCR7. In ad-
dition, CXCR7 is more effective than CXCR4 as a competitor for the
CXCR7-NLuc/β-arrestin 2–CLuc PCA.
CXCR7 Preferentially Interacts with β-Arrestin 2 Relative
to β-Arrestin 1
Epithelial cells express two different β-arrestin molecules, β-arrestin 1
and β-arrestin 2. Class A 7-TM receptors preferentially interact with
Figure 4. Ligand-dependent colocalization of CXCR7 and β-arrestin 2. 293T cells were transfected with CXCR7-GFP and β-arrestin
2–mCherry and imaged before and after incubation with 300 ng/ml CXCL12 for 2 hours. Green, red, and merged fluorescence images
are shown under basal conditions and after treatment with CXCL12. Blue arrows show colocalization of CXCR7-GFP and β-arrestin
2–mCherry in intracellular structures.
Figure 5. Induction of complementation signal in cells coexpressing
nonbioluminescent CXCR4 or CXCR7. 293T cells stably expressing
the CXCR7/β-arrestin 2 PCA were transfected with CXCR4-mPlum,
CXCR7-mPlum, or unfused mPlum control. Cells were treated with
300 ng/ml CXCL12 for 2 hours before quantifying firefly luciferase
activity for association of CXCR7 and β-arrestin 2. Data are pre-
sented as percent induction of bioluminescence relative to mPlum
control set at 100% and are representative of three independent
experiments (n = 4 per condition). *P < .05; **P < .01.
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β-arrestin 2, whereas class B receptors have similar affinity for form-
ing complexes with β-arrestin 1 or β-arrestin 2 [45]. To investigate
the association of CXCR7 with β-arrestin 1 or β-arrestin 2, we tran-
siently transfected cells with CXCR7-NLuc and β-arrestin 1-CLuc or
β-arrestin 2–CLuc, respectively, and treated cells with increasing con-
centrations of CXCL12 for 1 hour before measuring luciferase activ-
ity. For CXCR7-NLuc and β-arrestin 2–CLuc, CXCL12 produced
concentration-dependent increases in bioluminescence (Figure 6).
Luciferase activity could be detected above basal levels in untreated
cells at 10 ng/ml CXCL12 (the lowest tested concentration; P < .05)
and bioluminescence increased by ≈2.5-fold at 1 μg/ml CXCL12 (P <
.01). Incubation with CXCL12 had minimal effects on the CXCR7–β-
arrestin 1 PCA. Relative to untreated cells, luciferase activity increased by
≈1.4-fold at 10 ng/ml CXCL12 and did not rise further through 1μg/ml
CXCL12 (P < .05). These data establish that CXCR7 preferentially in-
teracts with β-arrestin 2 in response to chemokine binding.
Small Molecules Regulate Recruitment of β-Arrestin 2
to CXCR7
Recent studies have identified small-molecule compounds (CCX733
and CCX754) that block binding of CXCL11 and CXCL12 to CXCR7
with a half maximal inhibitory concentration of ≈5 nM in ligand bind-
ing assays performed in vitro at 4°C [47]. CCX754 also inhibits tumor
growth in mouse xenograft models of cancer [20]. We initially tested
effects of these compounds to block CXCL11- and CXCL12-dependent
recruitment of β-arrestin 2 to CXCR7. Stable 293Treporter cells were
incubated with increasing concentrations of either compound for
30 minutes before treating with 100 ng/ml CXCL11 or CXCL12
for 2 hours. Unexpectedly, neither compound inhibited chemokine-
dependent increases in bioluminescence from recruitment of β-arrestin
2 to CXCR7 (Figure 7, A and B). Treatment with 10 nMCCX733 (P <
.01) or CCX754 (P < .05) activated the CXCR7/β-arrestin 2 PCA
with dose-dependent increases through 1 μM. Incubation with 1 μM
CCX733 and CCX754 increased bioluminescence by approximately
four- and six-fold above untreated cells, respectively, after 2.5 hours.
These data establish that both small molecules function similarly to
chemokine ligands to drive recruitment of β-arrestin 2 to CXCR7 under
physiologic conditions.
Having determined that two small-molecule inhibitors of CXCL11
and CXCL12 binding to CXCR7 functioned as agonists, we investigated
the effects of two different inhibitors of CXCR4, namely, AMD3100
and TF14013, on the recruitment of β-arrestin 2 to CXCR7. We incu-
bated 293T/β-arrestin 2 reporter cells with various concentrations of
AMD3100 or TF14013 for 30 minutes before adding 100 ng/ml
Figure 6. Enhanced reporter signal from association of CXCR7
with β-arrestin-2. 293T cells were transiently transfected with
CXCR7-NLuc and β-arrestin 1-CLuc or β-arrestin 2–CLuc, respec-
tively. Cells were cotransfected with GL to normalize for transfec-
tion efficiency. Forty-eight hours after transfection, cells were
treated with increasing concentrations of CXCL12. Firefly luciferase
bioluminescence produced by living cells was quantified 1 hour
after adding chemokine (n= 4 per condition), and these values were
normalized to GL activity. Bioluminescence data for chemokine-
stimulated recruitment of β-arrestin 1 or β-arrestin 2 to CXCR7 are
expressed as mean values relative to bioluminescence in unstimu-
lated cells. Error bars, SEM. Data are representative of three inde-
pendent experiments. *P < .05; **P < .01.
Figure 7. Regulation of β-arrestin 2 recruitment to CXCR7 by small
molecules. (A and B) 293T cells stably transduced with the CXCR7/
β-arrestin 2 PCA were pretreated with increasing concentrations
of CXCR7-targeted small molecules CCX733 (A) or CCX754 (B)
for 30 minutes. Cells were then maintained in the same concentra-
tion of CCX733 or CCX754 and treated with 100 ng/ml CXCL11 or
CXCL12 or vehicle control for an additional 2 hours before quan-
tifying bioluminescence from firefly luciferase. Luminescence data
were normalized to a value of 1 for cells not treated with either small
molecule or chemokine. Data are mean values ± SEM (n = 4 per
condition, representative of three independent experiments). *P <
.05; **P < .01.
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CXCL12 or BSA control for an additional 2 hours. At concentrations as
low as 100 nM, treatment with TF14013 increased bioluminescence
above untreated cells (P < .05), and luciferase activity increased by
approximately two-fold in response to 1 μM of this compound (P <
.01; Figure 8). Although AMD3100 did not alter the PCA signal at
100 nM, there was a 1.5-fold increase in bioluminescence in cells treated
with 1 μM of this agent (P < .05). Neither TF14013 nor AMD3100
significantly altered the effects of CXCL12 to drive the recruitment of
β-arrestin 2 to CXCR7, supporting results with other assay systems
showing that these compounds do not alter binding of CXCL12 to
CXCR7 [20,48].
Interaction of CXCR7 and β-Arrestin 2 Regulates
Accumulation of CXCL12
A recent study demonstrated that cells expressing CXCR7 accumu-
late CXCL12 [24], leading us to investigate effects of β-arrestin 2 on
this process. We transduced CXCR7-GFP into MEF cell lines derived
from mice lacking β-arrestin 2 or matched wild-type animals. These
stable β-arrestin 2−/− and wild-type MEF cell lines had similar levels
of CXCR7 on cell membranes as determined by flow cytometry
(Figure 9A). We incubated cells for 1 hour with either ≈10 ng/ml
CXCL12-GL or a comparable amount of unfused GL based on bio-
luminescence. Incubations also included 100 nM of CXCR7-specific
compounds CCX733 or CCX754 or matched vehicle control. After
incubating for 1 hour, cells were then washed with PBS or with an
acidic solution, the latter of which removes chemokines bound to the
cell surface.
Wild-type– and β-arrestin 2−/−CXCR7-GFP MEFs washed only
with PBS had essentially the same levels of CXCL12-GL (Figure 9B),
showing that the absence of β-arrestin 2 did not alter total amounts of
chemokine bound to the cell surface. This result is consistent with pre-
vious research showing that binding of CXCL12 to cell membranes is
mediated predominantly through proteoglycans expressed on the sur-
face of cells [49]. By comparison, washing cells with an acidic solution
to remove chemokine on the cell surface revealed that MEFs lacking
β-arrestin 2 had significantly lower levels of internalized CXCL12-GL
compared with wild-type cells (P < .01; Figure 9C ). However, levels
of intracellular CXCL12-GL remained readily detectable above back-
ground in β-arrestin 2−/−CXCR7-GFP MEFs, implying that CXCR7-
dependent uptake of chemokines has both β-arrestin 2–dependent
and –independent components. Both cell types had comparable levels
of unfusedGL that wereminimally above background under conditions
of PBS or acid wash, demonstrating that greater accumulation of intra-
cellular CXCL12-GL in wild-type MEFs was not due to nonspecific
increases in fluid-phase endocytosis (data not shown).
Incubation with specific CXCR7 inhibitors CCX733 or CCX754
reduced cell-associated CXCL12-GL in cells washed with PBS (P <
.05), but the extent of inhibition did not differ between wild-type–
and β-arrestin 2−/−CXCR7-GFP MEFs (Figure 9B). Pharmacologic
inhibition of CXCR7 had a more pronounced effect to diminish
intracellular uptake of CXCL12 in wild-type CXCR7-GFP MEFs
under acid wash conditions (Figure 9C ; P < .01), showing that these
compounds are more effective at blocking CXCR-dependent inter-
nalization of CXCL12-GL relative to total binding of chemokine to
cells. Inhibitors of CXCR7 also reduced intracellular CXCL12-GL
in β-arrestin 2−/−CXCR7-GFP MEFs, albeit to a lesser extent than
in cells with wild-type β-arrestin 2 (P < .05). This result in β-arrestin
2−/−CXCR7-GFP MEFs further suggests that CXCR7 also internalizes
CXCL12-GL through a β-arrestin 2–independent pathway.
To establish that these effects were not dependent on the over-
expression of CXCR7, we also performed experiments in untransduced
β-arrestin 2−/− and wild-type MEFs. These cells express CXCR7 endog-
neously with slightly higher amounts of receptor at the surface of wild-
type MEFs (Figure 9A). Similar to results with cells overexpressing
CXCR7, wild-type MEFs accumulated significantly more intracellular
CXCL12-GL than β-arrestin 2−/− cells, and this uptake was inhibited with
CCX733 and CCX754. Collectively, these data show that β-arrestin 2
regulates the predominant pathway for CXCR7-dependent uptake
of chemokines, emphasizing a key biologic function for the CXCR7–β-
arrestin 2 protein interaction that is the basis of our imaging assay.
In Vivo Recruitment of β-Arrestin 2 to CXCR7
Recent studies show that CXCR7 is expressed by malignant cells
in a variety of common cancers, including breast, prostate, and lung
[17,18]. Having determined that small-molecule inhibitors of CXCR7–
dependent tumor growth also cause association of the receptor with
β-arrestin 2, we investigated to what extent this interaction could be de-
tected in living animals. To accomplish this goal, we first established
MDA-MB-231 human breast cancer cells stably transduced with the
CXCR7/β-arrestin 2 PCA reporter. Similar to 293T cells, 231 reporter
cells show dose-dependent increases in bioluminescence in response to
CXCL11 or CXCL12. After 2 hours of incubation, CXCL11 and
CXCL12 produced approximately three- and four-fold increases in bio-
luminescence above baseline levels, respectively (Figure 10A; P < .001).
Treatment of these 231 cells with CCX733 and CCX754 also enhanced
luciferase activity (P < .01; Figure 10B), confirming that these molecules
drive interactions between CXCR7 and β-arrestin 2.
We injected 231 reporter cells as orthotopic tumor xenografts into
mammary fat pads of female SCID mice to reproduce the expression
of CXCR7 in human breast cancer. We used bioluminescence im-
aging to detect and quantify basal interactions between CXCR7 and
β-arrestin 2 in the tumor microenvironment. Images showed low levels of
Figure 8. Effects of CXCR4-targeted agents on association of CXCR7
with β-arrestin 2. Stably transduced CXCR7/β-arrestin 2 PCA reporter
cells were treated for 30 minutes with CXCR4-targeted inhibitors
AMD3100 or TF14013 before addition of 100 ng/ml CXCL12 or con-
trol for an additional 2 hours before quantifying luciferase activity.
Data are mean values ± SEM for luminescence relative to reporter
activity in cells not treated with either CXCR4-targeted agent or
CXCL12 (n = 4 per condition, representative of 2 independent ex-
periments). *P < .05; **P < .01.
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bioluminescence, consistent with the basal association of these proteins
identified in cell culture studies. We then treated mice with 100 mg/kg
of CCX754 injected subcutaneously, which produces serum levels that
peak ≈1 hour later and subsequently decline to very low levels within
24 hours [20]. This route of administration has been used previously
to block CXCR7-dependent tumor growth in mouse models. One hour
after administering CCX754, in vivo imaging showed activation of the
PCA for association of CXCR7 and β-arrestin 2 with luciferase activity
≈1.5-fold above baseline levels (Figure 10, C and D; P < .05). When
these same mice were imaged 8 hours after administering this com-
pound, reporter activity had returned to baseline levels. Subsequent
treatment with vehicle control did not alter bioluminescence, whereas
a second dose of 100 mg/kg of CCX754 again increased luciferase ac-
tivity from the CXCR7/β-arrestin 2 PCA reporter. We also doubled
the dose of CCX754 administered to mice to 200 mg/kg, resulting in
a significantly greater increase in reporter activity (approximately three-
fold above pretreatment levels) 1 hour after injecting the compound (P <
.01). Collectively, these data establish a specific dose-dependent activa-
tion of CXCR7 and recruitment of β-arrestin 2 in a living animal model
of human breast cancer.
Discussion
CXCR7 is the most recently identified chemokine receptor, binding
with high affinity to both CXCL11 and CXCL12. Although chemo-
kine receptor CXCR3 was known to bind chemokines CXCL9 and
Figure 9. β-arrestin 2 regulates CXCR7-dependent accumulation of CXCL12. (A) Expression of CXCR7 on the cell membrane of wild-type
and β-arrestin 2−/− MEFs was determined by flow cytometry. Histogram plots are shown for MEFs stably transduced with CXCR7-GFP
and endogenous CXCR7 in untransduced cells. Open symbol denotes isotype control antibody and filled symbol is staining with antibody
to CXCR7. (B and C) CXCR7-GFP–wild-type and β-arrestin 2−/− MEFs were incubated with ≈10 ng/ml CXCL12-GL for 1 hour and then
washed twice with either PBS (B) or an acidic solution to remove chemokine from the cell surface (C) before quantifying bioluminescence.
Data are mean values ± SEM for photons from CXCL12-GL normalized to bioluminescencemeasured in wild-type–CXCR7-GFPMEFs treated
with vehicle control (n = 4 per condition, representative of three independent experiments). (D) Untransduced wild-type and β-arrestin 2−/−
MEFs were incubated with ≈10 ng/ml CXCL12-GL for 1 hour and then washed with acidic solution as described in C (n = 4 per condition,
representative of two independent experiments). *P < .05; **P < .01.
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CXCL10 in addition to CXCL11, the discovery of CXCR7 as a second
receptor for CXCL12 refuted previous conclusions that CXCL12 and
CXCR4 comprised a unique ligand-receptor pair. As a result, there is
intense interest in determining independent and integrated functions of
CXCR7 versus CXCR4 in biologic effects of CXCL12 in cancer and
other diseases. Several different cellular phenotypes have been attrib-
uted to CXCR7 either alone or in combination with CXCR4. How-
ever, many proposed functions of CXCR7 have not been consistent
across different cell types and model systems. To understand general and
cell type–specific functions of CXCR7 in normal physiology and cancer,
it is essential to define molecular interactions of this receptor with poten-
tial downstream effector molecules in intact cells and living animals.
We used a firefly luciferase PCA to quantify association of CXCR7
with the cytosolic adapter protein β-arrestin 2, a molecule that is cen-
tral to the biologic effects of many 7-TM receptors [50]. In the
absence of chemokine ligand, the interaction between CXCR7 and
Figure 10. In vivo recruitment of β-arrestin 2 to CXCR7 in breast tumor xenografts. (A and B) MDA-MB-231 human breast cancer cells stably
transduced with the CXCR7-NLuc/β-arrestin 2–CLuc PCA were treated with increasing concentrations of chemokines CXCL11 or CXCL12
(A) or CXCR7-targeted small molecules CCX733 or CCX754 (B) for 2 hours. Reporter bioluminescence was normalized to luciferase activity
in control cells (relative luminescence of 1), and these data are depicted as mean values ± SEM (n = 4 per condition, representative of
two independent experiments). (C) Female SCIDmice were implanted with orthotopic tumor xenografts of MDA-MB-231 reporter cells. Bio-
luminescence imaging was performed under baseline conditions (Pre-TX) to measure association of CXCR7 with β-arrestin 2. The following
day, mice were treated with CCX754 at the doses shown in the figure and then imaged 1 hour later. Paired images from pretreatment and
1 hour studies are shown for two different mice. Bioluminescence is presented as a pseudocolor scale, with red being the highest and
blue being the lowest levels of emitted photons. The same pseudocolor scale was used for matched pairs of images. (D) Quantified bio-
luminescence imaging data for mice under baseline conditions, 1 or 8 hours after treatment with CCX754, or vehicle control. Data are mean
values ± SEM when error bars are visible (n = 8 tumors). *P < .05; **P < .01; ***P < .001.
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β-arrestin 2 was significantly greater than that observed for control
pairs of CXCR7 and c-fos or FKBP12, showing a specific association
of CXCR7 and β-arrestin 2 under baseline conditions. Similar find-
ings have been reported previously for ligand-independent interactions
of CXCR4 and other 7-TM receptors with β-arrestin 2 [30,33,51].
Treatment with CXCL11 or CXCL12 significantly enhanced the in-
teraction of CXCR7 with β-arrestin 2, and each chemokine produced
comparable increases in bioluminescence from the PCA. Ligand-
dependent association of CXCR7 and β-arrestin 2 was verified by
fluorescence microscopy, which showed colocalization of both pro-
teins in intracellular structures induced by treatment with CXCL12.
In addition, we established that CXCR7 preferentially interacts with
β-arrestin 2 compared with the related β-arrestin 1 adapter protein,
as evidenced by the minimal change in bioluminescence produced
by the CXCR7/β-arrestin 1 PCA pair in response to CXCL12. Taken
together, these data establish that specific ligands drive recruitment of
β-arrestin 2 to CXCR7.
7-TM receptors have been classified broadly into class A and class
B families based on interactions with β-arrestin molecules [28,45]. In
response to ligand, class A receptors have transient interactions with
β-arrestin molecules, and these receptors recycle rapidly to the cell
membrane through early endosomes. Class A receptors also have higher
affinity binding to β-arrestin 2 versus β-arrestin 1. By comparison, class
B 7-TM receptors remain associated with β-arrestin molecules for sub-
stantially longer periods because these protein complexes traffic to late
endosomes and lysosomes. Class B 7-TM receptors also show com-
parable binding to both β-arrestin 1 and 2. Our data show that CXCR7
has properties of both class A and class B 7-TM receptors, differing
notably from the class A kinetics of CXCR4 and β-arrestin 2 [33].
As described in previous paragraphs, CXCR7 has significantly greater
association with β-arrestin 2, a characteristic of class A 7-TM receptors.
However, bioluminescence from the CXCR7-NLuc/β-arrestin 2–CLuc
PCA continues to increase over time through at least 4 hours as would
be expected for a class B receptor. These data suggest that stable com-
plexes of CXCR7 and β-arrestin 2 persist over time, potentially on
endosomes and other intracellular vesicular compartments. Increases
in bioluminescence also indicate that new protein complexes continue
to form during prolonged incubation with chemokine ligand, possibly
because of the ongoing synthesis of new proteins and/or stabilization
of existing proteins. Mixed patterns of class A and class B interactions
with β-arrestin 2 have been reported previously for somatostatin re-
ceptors [52].
One recently identified biologic function of CXCR7 is sequestration
of chemokine CXCL12, which is proposed to shape gradients of this
chemokine for signaling through CXCR4 [24]. Using wild-type and
β-arrestin 2−/− MEFs transduced with CXCR7, we established that
β-arrestin 2 is necessary for the efficient uptake of chemokine ligands
by CXCR7. We note that loss of β-arrestin 2 did not completely elimi-
nate accumulation of CXCL12 in MEFs, indicating that CXCR7 may
also use a β-arrestin 2–independent pathway for the uptake of chemo-
kine ligands. We are currently investigating mechanisms CXCR7-
dependent, β-arrestin 2–independent sequestration of chemokines.
Nevertheless, these data show functional relevance for the protein
interaction between CXCR7 and β-arrestin 2 and support the use of
our imaging assay to monitor activation of CXCR7.
Previous studies have shown that CXCR7-targeted small mole-
cules CCX733 and CCX754 inhibit binding of CXCL12 to CXCR7
at 4°C, a temperature at which endocytosis is blocked [20]. These
molecules have also been reported to limit cell adhesion in vitro
and growth of tumor xenografts in vivo [20,26]. Under physiologic
conditions, we determined that both of these molecules potently
drive association of CXCR7 with β-arrestin 2. In cell-based assays,
we detected recruitment of β-arrestin 2 to CXCR7 in response to
as little as 10 nM of compound, and effects of these compounds
on the interaction of CXCR7 and β-arrestin 2 were comparable to
those produced by chemokine ligands CXCL11 and CXCL12. In
addition to CXCR7-targeted small molecules, we determined that
agents directed against CXCR4 may also promote interactions be-
tween CXCR7 and β-arrestin 2. For AMD3100, this effect is modest
and occurs only at a high concentration (1 μM) that is substantially
greater than the half maximal effective concentration value (<100 nM)
reported previously for this compound in CXCR4 bioassays [53]. Simi-
lar effects of high concentrations of AMD3100 to promote recruit-
ment of β-arrestin 2 to CXCR7 have been described recently using
bioluminescence resonance energy transfer to detect interactions between
these two proteins [54]. In addition, we demonstrated a dose-dependent
activation of the CXCR7/β-arrestin 2 PCA with the peptide analog
TF14013 at concentrations as low as 100 nM in cell-based assays. These
data imply that biologic effects of both CXCR4-targeted molecules
potentially may be complicated by effects on CXCR7/β-arrestin 2 when
the agents are used at saturating concentrations in cells that express
both receptors.
One of the strengths of the firefly luciferase PCA is the ability to
quantify the magnitude and dynamics of protein interactions in cell-
based assays and then easily translate the system to mouse models.
Using in vivo bioluminescence imaging, we demonstrated that one of
the CXCR7-targeted compounds (CCX754) drives association of the
receptor with β-arrestin 2 in cancer cells in an orthotopic mouse model
of human breast cancer. Imaging data showed that the kinetics of asso-
ciation were consistent with previously reported data for pharmaco-
kinetics of this compound in mice [20]. In addition, we established
dose-dependent effects of this compound to activate the CXCR7/β-
arrestin 2 PCA in breast tumors, providing an in vivo assay for pharmaco-
dynamics of potential therapeutic agents targeted against CXCR7.
Results from the cell-based and animal experiments imply that effects
of these CXCR7-targeted agents on tumor growth are not dependent
solely on blocking binding of CXCL11 or CXCL12 to the receptor. Po-
tentially, these compounds drive association of CXCR7 and β-arrestin 2
without activating the same molecular pathways that are controlled by
chemokine binding to CXCR7. Through such a mechanism, CXCR7
may internalize from the cell surface and no longer be available for
binding CXCL12 and/or interacting with other intracellular molecules.
Studies are ongoing to identify cell signaling pathways regulated by
CXCR7. Defining these pathways and to what extent there is differen-
tial regulation by chemokines versus small molecules will advance efforts
to target CXCR7 for cancer therapy.
CXCR7 seems to have critical functions in normal development, as
evidenced by embryonic lethality of mice lacking this gene, and the
receptor is also upregulated in disease processes including cancer and
stroke [17,18,25,55]. These findings highlight important biologic
functions of this newly discovered chemokine receptor and emphasize
the need to identify molecular regulation of CXCR7. The current study
establishes ligand-dependent interaction of CXCR7 with β-arrestin 2
with kinetics that are distinct from CXCR4, providing new insights
into functional differences between these two receptors and mecha-
nisms of action for CXCR7 as a signaling and/or decoy receptor. The
firefly luciferase PCA provides a new quantitative assay for studies of
CXCR7 and β-arrestin 2 in intact cells that would be compatible with
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high-throughput screening. In addition, we have demonstrated that the
reporter can be used to image activation of CXCR7 in living animals,
providing a noninvasive assay for studying CXCR7 in the tumor micro-
environment and measuring pharmacodynamics of candidate thera-
peutic agents. Ongoing studies with this PCA will continue to define
mechanisms of action for CXCR7 in tumor progression and metastasis
and enable pharmacologic studies to develop CXCR7-targeted com-
pounds as therapeutic agents in cancer and other diseases.
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